SPYRE THERAPEUTICS, INC.

Analyst Reco. Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Real-time Estimate Cboe BZX Other stock markets 12:14:26 2024-04-29 pm EDT			5-day change	1st Jan Change
35.61 ^USD	+6.11%		+5.87%	+63.80%

Apr. 19	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT
Apr. 19	Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating	Mar. 26	MT
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12	Mar. 01	MT
BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32	Dec. 20	MT
Stifel Adjusts Price Target on Spyre Therapeutics to $27 From $23, Keeps Buy Rating	Dec. 18	MT
Jefferies Initiates Spyre Therapeutics at Buy Rating With $31 Price Target	Dec. 11	MT
Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to $0.50 From $0.35, Maintains Equal-Weight Rating	23-08-16	MT
Stifel Initiates Aeglea BioTherapeutics With Buy Rating, $0.90 Price Target	23-07-25	MT
LifeSci Capital Downgrades Aeglea BioTherapeutics to Market Perform From Outperform	23-04-12	MT
JonesTrading Downgrades Aeglea BioTherapeutics to Hold From Buy	23-04-12	MT
Piper Sandler Lifts Aeglea BioTherapeutics to Overweight From Neutral, Price Target to $1.50 From $1	22-10-28	MT
Wells Fargo Lifts Aeglea BioTherapeutics to Overweight From Equalweight, Price Target to $2 From $1.50	22-10-28	MT
Needham Downgrades Aeglea BioTherapeutics to Hold From Buy	22-06-03	MT
Piper Sandler Downgrades Aeglea BioTherapeutics to Neutral From Overweight, Cuts Price Target to $1 From $4, Shares Dive 46%	22-06-02	MT
HC Wainwright Downgrades Aeglea BioTherapeutics to Neutral From Buy, Cuts Price Target to $1 From $17	22-06-02	MT
Piper Sandler Adjusts Price Target for Aeglea BioTherapeutics to $4 From $7, Maintains Overweight Rating	22-05-23	MT
Piper Sandler Adjusts Aeglea BioTherapeutics' Price Target to $7 From $9, Reiterates Overweight Rating	22-05-09	MT
HC Wainwright Adjusts Price Target on Aeglea BioTherapeutics to $17 From $20, Reiterates Buy Rating	22-05-06	MT
AEGLEA BIOTHERAPEUTICS : HC Wainwright Adjusts Aeglea BioTherapeutics' Price Target to $15 from $17, Keeps Buy Rating	20-11-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer